Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. 1999

P Devillier, and N Baccard, and C Advenier
Laboratoire de Pharmacologie et Toxicologie, Ho@a5pital Maison Blanche, Centre Hospitalier et Universitaire de Reims, 45, rue Cognacq Jay, Reims, Cedex, 51092, France.

Asthma is a chronic inflammatory disease associated with airflow obstruction. Airflow obstruction results from contraction of airway smooth muscle, mucosal oedema, increased secretion of mucus and infiltration of the airway wall by inflammatory cells, particularly eosinophils. Leukotrienes are thought to contribute to the pathophysiology of asthma. Leukotrienes are synthesised from arachidonic acid by a specific synthesis pathway whose key enzyme is 5-lipoxygenase. Cysteinyl leukotrienes (leukotrienes C4, D4 and E4) have been shown to mimic all the pathologic changes that are characteristic of asthma, whereas leukotriene B4 does not appear to exert biological properties relevant to asthma. Cysteinyl leukotrienes bind to two receptor subtypes: CysLT1 and CysLT2. Most of the biological properties of cysteinyl leukotrienes relevant to asthma are mediated through CysLT1 receptor stimulation.

UI MeSH Term Description Entries
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D015289 Leukotrienes A family of biologically active compounds derived from arachidonic acid by oxidative metabolism through the 5-lipoxygenase pathway. They participate in host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation. They have potent actions on many essential organs and systems, including the cardiovascular, pulmonary, and central nervous system as well as the gastrointestinal tract and the immune system. Leukotriene
D016084 Bronchoconstriction Narrowing of the caliber of the BRONCHI, physiologically or as a result of pharmacological intervention. Bronchial Constriction,Bronchial Constrictions,Bronchoconstrictions,Constriction, Bronchial,Constrictions, Bronchial
D018077 Receptors, Leukotriene Cell-surface receptors that bind LEUKOTRIENES with high affinity and trigger intracellular changes influencing the behavior of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes LTB4; LTC4; LTD4; and LTE4. Leukotriene Receptors,Receptors, SRS-A,SRS-A Receptors,Leukotriene Receptor,Receptors, Leukotrienes,SRS-A Receptor,Slow Reacting Substance of Anaphylaxis Receptors,Slow Reaction Substance of Anaphylaxis Receptors,Leukotrienes Receptors,Receptor, Leukotriene,Receptor, SRS-A,Receptors, SRS A,SRS A Receptor,SRS A Receptors
D018927 Anti-Asthmatic Agents Drugs that are used to treat asthma. Anti-Asthmatic,Anti-Asthmatic Agent,Anti-Asthmatic Drug,Antiasthmatic,Antiasthmatic Agent,Antiasthmatic Drug,Anti-Asthmatic Drugs,Anti-Asthmatics,Antiasthmatic Agents,Antiasthmatic Drugs,Antiasthmatics,Agent, Anti-Asthmatic,Agent, Antiasthmatic,Agents, Anti-Asthmatic,Agents, Antiasthmatic,Anti Asthmatic,Anti Asthmatic Agent,Anti Asthmatic Agents,Anti Asthmatic Drug,Anti Asthmatic Drugs,Anti Asthmatics,Drug, Anti-Asthmatic,Drug, Antiasthmatic,Drugs, Anti-Asthmatic,Drugs, Antiasthmatic
D020024 Leukotriene Antagonists A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. Leukotriene Antagonist,Leukotriene Receptor Antagonist,Leukotriene Receptor Antagonists,Antagonists, Leukotriene,Receptor Antagonists, Leukotriene,Antagonist, Leukotriene,Antagonist, Leukotriene Receptor,Antagonists, Leukotriene Receptor,Receptor Antagonist, Leukotriene

Related Publications

P Devillier, and N Baccard, and C Advenier
January 1999, Pulmonary pharmacology & therapeutics,
P Devillier, and N Baccard, and C Advenier
February 1997, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
P Devillier, and N Baccard, and C Advenier
September 2009, The Journal of allergy and clinical immunology,
P Devillier, and N Baccard, and C Advenier
January 1997, Journal de pharmacie de Belgique,
P Devillier, and N Baccard, and C Advenier
August 2006, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
P Devillier, and N Baccard, and C Advenier
October 2012, Paediatric drugs,
P Devillier, and N Baccard, and C Advenier
January 2002, Allergy,
P Devillier, and N Baccard, and C Advenier
January 1998, Nederlands tijdschrift voor geneeskunde,
P Devillier, and N Baccard, and C Advenier
May 2000, Allergy,
P Devillier, and N Baccard, and C Advenier
November 2005, Drug and therapeutics bulletin,
Copied contents to your clipboard!